Q32 Bio Appoints New Chief Medical and Development Officers

Q32 Bio, a biotechnology company, has announced the appointment of José Trevejo, M.D., Ph.D., as its new Chief Medical Officer (CMO) and Ellie Hershberger, Pharm.D., as its new Chief Development Officer (CDO).

Dr. Trevejo brings over 20 years of experience as a physician-scientist and biotechnology executive, with a background in dermatology and late-stage clinical development. His expertise is expected to aid in the advancement of the company's clinical programs.

Dr. Hershberger has over 30 years of experience in drug development, focusing on late-stage development operations. Her role as CDO will be instrumental in guiding Q32 Bio's development pipeline.

These appointments are effective immediately. The company continues its focus on advancing its therapeutic candidates.